Phase 2 Fibromyalgia Trial, Recruiting NCT06946940 Sponsor: Rambam Health Care Campus Condition: Fibromyalgia
Back to Fibromyalgia

Phase 2 Fibromyalgia Trial, Recruiting

NCT06946940
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (men and women) aged 30 years or older
  • People who have been diagnosed with fibromyalgia by a pain specialist using the 2016 diagnostic criteria, with symptoms that have lasted 12 months or more
  • People whose average pain level over the past week has been 6 or higher (on a standard pain scale)
  • People whose treating doctor considers them suitable to receive cannabis-based treatment
  • People who are still experiencing significant symptoms despite having already tried standard fibromyalgia treatments, including pain relievers, certain antidepressants (tricyclic and SNRI types), and anti-epileptic medications

Who may not be able to join:

  • People who have used cannabis in the past month
  • People with certain significant other health conditions, such as inflammatory arthritis, inflammatory bowel disease, or cancer (the trial doctor determines this on a case-by-case basis)
  • People with a personal or family history of psychotic disorders
  • People with a current or past anxiety disorder
  • People with any uncontrolled mental health condition
  • People with a current or past history of substance addiction or misuse
  • People who have been diagnosed with dementia or a cognitive (thinking/memory) impairment
  • People with a personal history of heart or cardiovascular disease
  • People who are pregnant, breastfeeding, or planning to become pregnant
  • People with a known allergy to any ingredient in cannabis oil
  • People with a history of seizures or epilepsy (not including simple febrile convulsions in childhood)
  • People with active liver disease
  • People with Inflammatory Bowel Disease (IBD)
  • People for whom cannabis-based medicine is otherwise medically unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Amir Minerbi, MD-PhD, Rambam Health Care Campus

Phone: +9724-7772040

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Rambam Health Care Campus
Registry
ClinicalTrials.gov
Start date
30 May 2024
Est. completion
1 May 2026

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

correlation of microbiome composition or serum metabolomics with pain reduction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov